Breast Cancer Clinical Trials

Showing 541-560 of 4,817 trials

CDK and Body Composition Study

NCT03697577

The goal of this study is to evaluate changes in body composition among patients who are treated with cyclin-dependent kinase (CDK) 4/6 inhibitors (abemaciclib, ribociclib, or palbociclib).

Breast Cancer

Montefiore Medical Center30 participantsStarted Jan 2019

The Bronx, New York, United States

COMPLETEDNA

The Effect on Attendance of an SMS Notification Prior to a Scheduled Screening Appointment in BreastScreen Norway

NCT07355569

This study has been designed as a randomized controlled trial including women invited to a national screening program for breast cancer in Norway, BreastScreen Norway in 2025. The program invites women aged 50-69 to biennial screening mammography. The study includes two substudies with the intervention of sending an SMS notification three days prior to the screening appointment in the first substudy and two days prior to the screening appointment in second study. The comparison is made between the study groups, where women are sent an SMS notification two or three days prior to their scheduled screening appointment and the control groups where women will not be sent an SMS notification about a scheduled screening appointment.

AttendanceBreast Cancer Screening

Norwegian Institute of Public Health133,770 participantsStarted Jan 2025

Oslo, Oslo, Norway

RECRUITINGPhase 3

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

NCT07362914

Investigating the Association Between Corticosteroid Use and Improvement in Doxorubicin Liposome-Induced Cutaneous Toxicity: Exploring the Feasibility and Mechanisms of Corticosteroids in Mitigating Liposomal Doxorubicin-Related Dermatologic Adverse Effects.

Breast Cancer

Fudan University182 participantsStarted Mar 2025

Shanghai, Shanghai Municipality, China

CDK and Body Composition Study

The Effect on Attendance of an SMS Notification Prior to a Scheduled Screening Appointment in BreastScreen Norway

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Related Searches

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Trans-RosaLEE Study: a Biomarker-directed, Translational Study

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

EXoPERT EMERALD Clinical Study

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence

REBECCA Real-world Early BrEast CanCer mAnagement

Breast Cancer Education to Prisoner Women

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer